Vibativ serves as a probably life-saving remedy in sufferers with hospital-acquired and ventilator-associated pneumonia ensuing from a spread of Gram-positive bacterial pathogens, together with these which can be thought of difficult-to-treat and are multidrug-resistant.
As a once-daily dosed antibiotic, Vibativ doesn’t require therapeutic drug monitoring, lowering well being care professionals’ publicity to the affected person.
“As a part of our function and mission in Tabuk to ship distinctive well being options and save lives of individuals all through the Center East nations we function in, we consider that Vibativ will present our physicians with a robust new software to battle multidrug-resistant infections together with MRSA, hospital-acquired pneumonia and ventilator-associated pneumonia,” stated Mohammed Al Hagbani, president of Astra Industrial Group.
“Vibativ is a life-saving product for sure difficult-to-treat infections and a key addition to Tabuk’s anti-infective portfolio, strengthening our main market place on this remedy space and delivering on our technique of constructing our specialty and revolutionary enterprise whereas additionally reinforcing our main place within the territory,” stated Wisam Alkhatib, vp of technique & enterprise growth at Tabuk Prescribed drugs.
“Tabuk is a well-respected pharmaceutical firm with a robust distribution community all through the Center East, and we’re proud to accomplice with them to introduce Vibativ to this market,” stated A.J. Kazimi, CEO of Cumberland Prescribed drugs. “They’ve the sources and expertise to make sure that Vibativ reaches as many sufferers throughout the territory as doable, and we stay up for a profitable partnership.”
Vibativ® (telavancin) Injection was found in a analysis program devoted to discovering new antibiotics for critical infections on account of Staphylococcus aureus (S. aureus) and different Gram-positive micro organism, together with MRSA and MSSA. Vibativ is a once-daily, injectable lipoglycopeptide antibiotic with in vitro efficiency, bactericidal exercise inside six hours, and penetration into goal an infection websites. The drug is permitted within the U.S. for the remedy of grownup sufferers with hospital-acquired and ventilator-associated bacterial pneumonia (HABP/VABP) attributable to inclined isolates of S. aureus when different remedies should not appropriate.
As well as, Vibativ is permitted within the U.S. for the remedy of grownup sufferers with sophisticated pores and skin and pores and skin construction infections (cSSSI) attributable to inclined isolates of Gram-positive micro organism, together with S. aureus, each methicillin-susceptible (MSSA) and methicillin-resistant (MRSA) strains. The product labeling additionally describes the usage of Vibativ in treating sufferers whose pneumonia or pores and skin an infection is sophisticated by concurrent bacteremia. The product’s confirmed efficacy towards difficult-to-treat Gram-positive infections has been demonstrated in a number of giant, multinational registrational research, which concerned one of many largest cohorts of sufferers with S. aureus infections studied up to now. Importantly, these research demonstrated considerably greater remedy charges for Vibativ as in comparison with vancomycin in HABP/VABP on account of any single Gram-positive pathogen or S. aureus with vancomycin MIC ≥1 µg/mL. Moreover, there’s intensive and well-documented proof of the drug’s in vitro efficiency and in vivo exercise towards a broad assortment of Gram-positive bacterial pathogens, together with these which can be thought of difficult-to-treat and multidrug-resistant.
For full prescribing info, together with essential security info go to www.vibativ.com.
About Tabuk Pharmaceutical Manufacturing Co.
Tabuk Pharmaceutical Manufacturing Firm is a number one Saudi pharmaceutical firm with a regional presence within the Center East and North Africa. Tabuk Prescribed drugs develops, manufactures, markets and distributes varied branded generics, along with manufacturing pharmaceutical merchandise for famend worldwide companions at its manufacturing websites in Saudi Arabia, as a part of its steady efforts to cowl the wants of sufferers by offering prime quality medicines. Tabuk Prescribed drugs is a serious participant within the pharmaceutical sector not solely within the Kingdom of Saudi Arabia, but in addition all through the Center East and North Africa, because of its 4 state-of-art manufacturing websites situated in Tabuk and Dammam within the Kingdom, in addition to in Sudan and Algeria, and orchestrated by a crew of greater than 2,400 staff. Tabuk Prescribed drugs reaches sufferers in 17 nations within the Center East and Africa, along with futuristic plans to develop its presence within the area.
About Cumberland Prescribed drugs
Cumberland Prescribed drugs Inc. is a specialty pharmaceutical firm targeted on the supply of high-quality, prescription manufacturers designed to enhance affected person care. The corporate develops, acquires, and commercializes merchandise for the hospital acute care, gastroenterology, and rheumatology market segments. The corporate’s portfolio contains eight FDA-approved manufacturers, together with Sancuso®, which Cumberland acquired in December 2021. The corporate additionally has a sequence of Part II scientific applications underway evaluating its ifetroban product candidate in sufferers with cardiomyopathy related to Duchenne Muscular Dystrophy, in addition to Systemic Sclerosis, and Aspirin-Exacerbated Respiratory Illness.
See extra info on Cumberland Pharmaceutical’s web site at www.cumberlandpharma.com.
This press launch incorporates forward-looking statements, that are topic to sure dangers and replicate Cumberland’s present views on future occasions primarily based on what it believes are affordable assumptions. No assurance will be on condition that these occasions will happen. As with all enterprise, all phases of Cumberland’s operations are topic to components exterior of its management, and anybody or mixture of those components might materially have an effect on Cumberland’s outcomes of operations. These components embody market situations, competitors, an incapacity of producers to supply Cumberland’s merchandise on a well timed foundation, failure of producers to adjust to rules relevant to pharmaceutical producers, sustaining an efficient gross sales and advertising infrastructure, pure disasters, public well being epidemics, and different occasions past its management as extra totally mentioned within the firm’s most up-to-date Kind 10-Q and any further updates filed with the SEC. There will be no assurance that outcomes anticipated by the corporate might be realized or that they’ll have the anticipated results. Readers are cautioned to not place undue reliance on forward-looking statements, which converse solely as of the date hereof. The corporate doesn’t undertake any obligation to publicly revise these statements to replicate occasions after the date hereof.
SOURCE Cumberland Prescribed drugs Inc.